Business Description
CytoMed Therapeutics Ltd
ISIN : SGXZ17669631
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 15.15 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-Equity | 0.04 | |||||
Debt-to-EBITDA | -0.16 | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -35.5 | |||||
3-Year EPS without NRI Growth Rate | -26.6 | |||||
3-Year FCF Growth Rate | -48.1 | |||||
3-Year Book Growth Rate | 181 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 62.95 | |||||
9-Day RSI | 54.36 | |||||
14-Day RSI | 52.89 | |||||
6-1 Month Momentum % | 35.93 | |||||
12-1 Month Momentum % | -23.01 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 21.52 | |||||
Quick Ratio | 21.52 | |||||
Cash Ratio | 18.07 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -1.8 | |||||
Shareholder Yield % | 5.48 |
Profitability Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -26.66 | |||||
ROA % | -24.79 | |||||
ROIC % | -122.17 | |||||
ROC (Joel Greenblatt) % | -107.44 | |||||
ROCE % | -25.57 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 3.43 | |||||
Price-to-Tangible-Book | 3.55 | |||||
EV-to-EBIT | -9.36 | |||||
EV-to-EBITDA | -10.54 | |||||
EV-to-FCF | -8.99 | |||||
Price-to-Net-Current-Asset-Value | 5.13 | |||||
Price-to-Net-Cash | 6.24 | |||||
Earnings Yield (Greenblatt) % | -10.68 | |||||
FCF Yield % | -9.19 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:GDTC
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
CytoMed Therapeutics Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.196 | ||
Beta | 0 | ||
Volatility % | 88.61 | ||
14-Day RSI | 52.89 | ||
14-Day ATR ($) | 0.312012 | ||
20-Day SMA ($) | 2.28211 | ||
12-1 Month Momentum % | -23.01 | ||
52-Week Range ($) | 1.2 - 5.5 | ||
Shares Outstanding (Mil) | 11.54 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
CytoMed Therapeutics Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
CytoMed Therapeutics Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
CytoMed Therapeutics Ltd Frequently Asked Questions
What is CytoMed Therapeutics Ltd(GDTC)'s stock price today?
When is next earnings date of CytoMed Therapeutics Ltd(GDTC)?
Does CytoMed Therapeutics Ltd(GDTC) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |